Figure 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

<p>Pharmacodynamic results in peripheral blood. Peripheral blood collected at baseline and various on-treatment time points (e.g., C2D1, C3D1, and C4D1) was assessed for changes in key immune cell subsets such as NK cells, CD8 T cells, CD4 T cells, and Tregs (<b>A</b>) and markers for immune cell activation (sCD25) and proliferation (Ki-67<sup>+</sup>; <b>B</b>). BL, baseline; C, cycle; D, day.</p>